genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2023
Sarepta Therapeutics
Artificial Intelligence
AI, Cell/Gene Therapy, Precision Medicine Drive Bullish Biotech Investment
Alex Philippidis
-
June 22, 2023
22
Drug Discovery
Door Busters: Entrada Therapeutics Is Engaging Inaccessible Intracellular Targets
Jonathan D Grinstein, PhD
-
June 5, 2023
20
Drug Discovery
FDA Lifts Clinical Hold on Pfizer DMD Gene Therapy Linked to Patient Death
Alex Philippidis
-
April 28, 2022
2
GEN Edge
Top 5 Reasons behind the Biopharma Bear Market
Alex Philippidis
-
February 14, 2022
0
A-Lists
Ten Life Science Analysts to Watch in 2020
Alex Philippidis
-
January 28, 2020
0
Genome Editing
Roche Buys Ex-U.S. Rights to Sarepta DMD Gene Therapy Candidate SRP-9001 for Up-to-$2.85B+
Alex Philippidis
-
December 23, 2019
0
A-Lists
10 Takeover Targets to Watch This Fall
Alex Philippidis
-
September 9, 2019
1
Genome Editing
Sarepta to Acquire Myonexus for $165M, Broadening Muscular Dystrophy Gene Therapy Pipeline
Alex Philippidis
-
February 27, 2019
0
News
Sarepta Acquires U.S., ex-European Rights to Lysogene MPS III Gene Therapy Candidate LYS-SAF302
GEN Staff Writer
-
October 15, 2018
0
News
FDA Lifts Holds on Epizyme Cancer Candidate, Sarepta DMD Gene Therapy
GEN Staff Writer
-
September 24, 2018
0
1
2
Page 1 of 2
Scroll Up